Sellas Life Sciences Group, Inc. (SLS) — SEC Filings
Sellas Life Sciences Group, Inc. (SLS) — 33 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 20 8-K, 6 10-Q, 2 DEF 14A.
View Sellas Life Sciences Group, Inc. on SEC EDGAR
Overview
Sellas Life Sciences Group, Inc. (SLS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: SELLAS Life Sciences Group, Inc. reported a net loss of $6.791 million for the three months ended September 30, 2025, an improvement from a net loss of $7.108 million in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $19.205 million, a significant reduction f
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant filing sentiment for Sellas Life Sciences Group, Inc. is neutral.
Filing Type Overview
Sellas Life Sciences Group, Inc. (SLS) has filed 6 10-Q, 20 8-K, 1 DEFA14A, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of SLS's 29 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$19.2M |
| EPS | -$0.20 |
| Debt-to-Equity | 0.13 |
| Cash Position | $44.3M |
| Operating Margin | N/A |
| Total Assets | $51.6M |
| Total Debt | $5.9M |
Key Executives
- Dr. Anthony S. Marfione, Jr.
- Dr. Jeffrey S. Boyer
- Dr. Angelos Stergiou
- Dr. John "Jack" B. Greene
Industry Context
SELLAS operates in the late-stage clinical biopharmaceutical sector, focusing on novel cancer therapeutics. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Success hinges on clinical trial outcomes and regulatory approvals, with a competitive landscape driven by innovation in immunotherapy and targeted therapies.
Top Tags
material-definitive-agreement (6) · 10-Q (4) · financing (4) · Biotechnology (3) · SEC Filing (3) · life-sciences (3) · public-offering (3) · Clinical Trials (2) · company-name-change (2) · corporate-filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and Cash Equivalents | $44.3M | Increased from $13.9M at Dec 31, 2024, a 218% increase, providing liquidity. |
| Net Loss (9 months) | $19.2M | Reduced from $24.1M in prior year, indicating improved operational efficiency. |
| Cash Used in Operations (9 months) | $23.5M | Lower than $28.2M in prior year, reflecting reduced cash burn. |
| October 2025 Inducement Proceeds | $29.1M | Additional capital secured post-quarter, extending cash runway. |
| September 2025 Inducement Proceeds | $22.0M | Significant capital infusion during the quarter. |
| January 2025 Offering Proceeds | $23.1M | Key financing event contributing to increased cash. |
| Accumulated Deficit | $267.3M | Indicates historical losses and the need for future profitability. |
| Shares Outstanding | 125,078,525 | Increased from 73,977,459 at Dec 31, 2024, reflecting significant dilution. |
| SEC File Number | 001-33958 | Identifier for the company's filings with the SEC |
| IRS Employer Identification No. | 20-8099512 | Tax identification number for the company |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating pre-commercial stage |
| Date of January 2025 Registered Direct Offering | 2025-01-29 | when common stock and pre-funded warrants were issued |
| Fiscal Year End | 2024 | Reporting period for the 10-K |
| Filing Date | 2025-03-20 | Date the 10-K was submitted to the SEC |
| Period End Date | 2024-09-30 | The 10-Q covers financial information up to this date. |
Frequently Asked Questions
What are the latest SEC filings for Sellas Life Sciences Group, Inc. (SLS)?
Sellas Life Sciences Group, Inc. has 33 recent SEC filings from Jan 2024 to Nov 2025, including 20 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SLS filings?
Across 33 filings, the sentiment breakdown is: 4 bullish, 2 bearish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Sellas Life Sciences Group, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sellas Life Sciences Group, Inc. (SLS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sellas Life Sciences Group, Inc.?
Key financial highlights from Sellas Life Sciences Group, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SLS?
The investment thesis for SLS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sellas Life Sciences Group, Inc.?
Key executives identified across Sellas Life Sciences Group, Inc.'s filings include Dr. Anthony S. Marfione, Jr., Dr. Jeffrey S. Boyer, Dr. Angelos Stergiou, Dr. John "Jack" B. Greene.
What are the main risk factors for Sellas Life Sciences Group, Inc. stock?
Of SLS's 29 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Sellas Life Sciences Group, Inc.?
Forward guidance and predictions for Sellas Life Sciences Group, Inc. are extracted from SEC filings as they are enriched.